ID   A549-CR
AC   CVCL_IP03
DR   BTO; BTO:0005816
DR   cancercelllines; CVCL_IP03
DR   Wikidata; Q54607013
RX   PubMed=26692948;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 10
//
RX   PubMed=26692948;
RA   Zhuo W.-L., Zhang L., Zhu Y., Zhu B., Chen Z.-T.;
RT   "Fisetin, a dietary bioflavonoid, reverses acquired cisplatin-resistance
RT   of lung adenocarcinoma cells through MAPK/survivin/caspase pathway.";
RL   Am. J. Transl. Res. 7:2045-2052(2015).
//